Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Roche Holdings Ltd ADR (RHHBY)

Roche Holdings Ltd ADR (RHHBY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 302,223,776
  • Shares Outstanding, K 6,848,488
  • Annual Sales, $ 64,165 M
  • Annual Income, $ 13,585 M
  • 60-Month Beta 0.41
  • Price/Sales 4.95
  • Price/Cash Flow 13.99
  • Price/Book 8.48
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 04/22/20
  • Annual Dividend & Yield 0.72 (1.63%)
  • Most Recent Dividend 0.719 on 03/19/20
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate 1.40
  • Number of Estimates 1
  • High Estimate 1.40
  • Low Estimate 1.40
  • Prior Year N/A
  • Growth Rate Est. (year over year) -99.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
42.5100 +1.36%
on 05/01/20
46.0000 -6.33%
on 04/28/20
-1.8000 (-4.01%)
since 04/27/20
3-Month
35.0400 +22.97%
on 03/23/20
46.0000 -6.33%
on 04/28/20
+2.3050 (+5.65%)
since 02/27/20
52-Week
32.6700 +31.89%
on 05/31/19
46.0000 -6.33%
on 04/28/20
+9.0900 (+26.74%)
since 05/24/19

Most Recent Stories

More News
Top Stock Reports for Alphabet, Visa & Bank of America

Top Stock Reports for Alphabet, Visa & Bank of America

V : 192.82 (-0.21%)
RHHBY : 43.0900 (-2.36%)
NVDA : 341.01 (-2.21%)
JPM : 101.37 (+5.79%)
GOOGL : 1,420.28 (-0.08%)
BAC : 25.98 (+7.00%)
Global Ophthalmology Drugs and Devices Market Size to expand at 6.16% CAGR through 2027

Selbyville, Delaware According to Market Study Report, Provides A Detailed Overview Of Ophthalmology Drugs and Devices Market With Respect To The Pivotal Drivers Influencing The Revenue Graph Of This Business...

AGN : 193.02 (+0.02%)
GSK : 40.94 (+0.47%)
RHHBY : 43.0900 (-2.36%)
SNPHF : 17.6500 (-2.19%)
VRX.TO : 30.80 (-3.33%)
The Zacks Analyst Blog Highlights: Bristol-Myers, Roche, AstraZeneca, Merck and Johnson & Johnson

The Zacks Analyst Blog Highlights: Bristol-Myers, Roche, AstraZeneca, Merck and Johnson & Johnson

JNJ : 144.89 (+0.23%)
AZN : 52.47 (-1.21%)
RHHBY : 43.0900 (-2.36%)
MRK : 77.55 (+0.38%)
BMY : 60.40 (+0.13%)
Roche Acquires Stratos Genomics, Presents Data on NMOSD Drug

Roche (RHHBY) acquires Stratos Genomics to advance the development of its nanopore sequencer as well as releases positive data on its NMOSD Drug.

RHHBY : 43.0900 (-2.36%)
MRK : 77.55 (+0.38%)
AMGN : 224.81 (+1.08%)
AGN : 193.02 (+0.02%)
Pharma Stock Roundup: FDA Ok's Cancer Drugs for New Use, JNJ Stops US Baby Powder Sales

FDA approves line extensions for Bristol-Myers (BMY), Roche (RHHBY) and AstraZeneca (AZN)/Merck's (MRK) drugs. J&J stops sales of talc-based baby powders in the United States and Canada.

JNJ : 144.89 (+0.23%)
AZN : 52.47 (-1.21%)
RHHBY : 43.0900 (-2.36%)
PFE : 37.41 (-0.21%)
MRK : 77.55 (+0.38%)
GSK : 40.94 (+0.47%)
BMY : 60.40 (+0.13%)
Roche highly accurate antibody test for COVID-19 goes live at more than 20 initial lab sites in the US

, /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced its Elecsys® Anti-SARS-CoV-2 antibody test is live at more than 20 commercial and hospital lab sites throughout , with plans in the...

RHHBY : 43.0900 (-2.36%)
Roche highly accurate antibody test for COVID-19 goes live at more than 20 initial lab sites in the US

INDIANAPOLIS , May 19, 2020 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced its Elecsys® Anti-SARS-CoV-2 antibody test is live at more than 20 commercial and hospital lab sites...

ROG : 112.07 (+0.64%)
RHHBY : 43.0900 (-2.36%)
Novartis Gets EC Approval for Gene Therapy Zolgensma in SMA

Novartis' (NVS) gene therapy, Zolgensma, obtains EC approval for spinal muscular atrophy.

BIIB : 301.46 (+1.89%)
RHHBY : 43.0900 (-2.36%)
NVS : 84.45 (-0.71%)
BAYRY : 17.1300 (+2.33%)
Roche's Tecentriq Gets FDA Approval for Metastatic NSCLC

Roche (RHHBY) gets FDA approval for the label expansion of Tecentriq into metastatic NSCLC as a first-line monotherapy.

AZN : 52.47 (-1.21%)
RHHBY : 43.0900 (-2.36%)
MRK : 77.55 (+0.38%)
BMY : 60.40 (+0.13%)
Vividion Therapeutics Announces Drug Discovery Collaboration with Roche Focused on Novel E3 Ligases

, /PRNewswire/ -- Vividion Therapeutics, a biotechnology company discovering and developing highly selective small molecule medicines that drug traditionally inaccessible targets, today announced that...

RHHBY : 43.0900 (-2.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade RHHBY with:

Key Turning Points

2nd Resistance Point 44.6633
1st Resistance Point 43.8767
Last Price 43.0900
1st Support Level 42.4267
2nd Support Level 41.7633

See More

52-Week High 46.0000
Last Price 43.0900
Fibonacci 61.8% 40.9079
Fibonacci 50% 39.3350
Fibonacci 38.2% 37.7621
52-Week Low 32.6700

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar